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INTRODUCTION
Systemic lupus erythematosus (SLE) is an auto-
immune disease characterized by a wide variety of
autoantibodies which may affect the skin, joints,
lungs, heart, serous membranes, nervous system
and other organs (1). SLE predominantly affects
women : the female : male ratio is about 9 : 1, and
more than 80% of the cases occur in women during
their child-bearing years (2). SLE is a chronic dis-
ease that is characterized by an undulating course
of exacerbations and remissions, and a major deter-
minant of long-term prognosis is organ damage con-
sequent to tissue injury that accompanies disease ac-
tivity and toxicity of therapy (3, 4). In the past 40
years, prognosis for patients with SLE has improved,
with 10-year survival now approximately 90% (5).
The improved prognosis may be due an earlier dis-
ease diagnosis, and due in part to the availability of
multiple serological tests for SLE, use of corticoster-
oids and other immunosuppressive agents and avail-
ability of renal dialysis and transplantation. Although
SLE patients are now possible to obtain long peri-
ods of remission in the disease course, some pa-
tients with SLE still carry a heavy burden of morbid-
ity due to organ damage, and repeat exacerbations
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during the disease course (6). Therefore, it is im-
portant to clarify features at onset to distinguish pa-
tients who developed a subsequent exacerbation
from those who did not. Studies of variables which
affect exacerbations in SLE have identified various
factors including clinical and laboratory features
(6, 7). However, the contribution of the initial clini-
cal and laboratory features to the course of SLE has
not yet been clarified. The aim of this study was to
evaluate which patients with SLE will develop an ex-
acerbation and whether factors can be identified to
predict the development of an exacerbation.
PATIENTS AND METHODS
Patients
Patients with SLE diagnosed at Tokushima Uni-
versity Hospital between December 1989 and No-
vember 2005 were included in this study. SLE was
diagnosed according to the criteria of American Col-
lege of Rheumatology for SLE (8). Table 1 shows
the baseline patient characteristics. Patients with
SLE consisted of 52 females and 5 males aged 40.2
17.2 y.o. on average (male ; 50.69.7 y.o., female ;
39.217.5 y.o.). Figure 1 shows age of patients at
the time of diagnosis of SLE, showing that the most
patients were diagnosed in twenties, and 64.9% of
patients were diagnosed when they were between
20 and 49 y.o.. As shown in Table 1, association of
other collagen vascular diseases was seen in 10 pa-
tients with SLE : 5 rheumatoid arthritis, 3 Sjogren’s
syndrome, a mixed connective tissue disease, and
a polymyositis. The complication of pleuritis and
pericarditis was found in 22 patients (38.6%) and
11 patients (19.3%), respectively. The complication
of lupus nephritis, pulmonary involvements and neu-
ropathy was found in 21 patients (36.8%), 12 patients
(21.1%) and 7 patients (12.3%), respectively.
SLE disease activity index (SLE-DAI) was calcu-
lated as a measure of systemic activity of the disease
at the time of the diagnosis (9). At each monthly
visit, levels of C3, C4, CH50 and anti-dsDNA anti-
bodies, complete blood cell counts, analyses of he-
patic and renal function, and urinalysis were exam-
ined. An exacerbation was defined as one or more
of the following 3 features : 1) a3-point change in
the SLE-DAI score, 2) a clinical exacerabation with
or without serologic activity. A serologic exacerba-
tion was defined as an elevation of anti-dsDNA an-
tibody levels by 25% (to the abnormal range) or a
decrease of C3 and CH50 by 25%, 3) an increase in
the dosage of corticosteroid or an addition of im-
munosuppressive agent was considered in tapering
of corticosteroid dosage. Diabetes mellitus and asep-
tic necrosis of the femoral head were complicated
in 10 patients (17.5%) and 6 patients (10.5%), respec-
tively, with SLE patients after the treatment with
corticosteroid (data not shown).
Figure 1. Age at the time of diagnosis. Closed columns show
male, and open columns show female.
Table 1 Patient characteristics at the time of diagnosis of SLE
Number of patients 57
Sex (M / F) 5 / 52
Average age (y.o.) 40.217.2
Other collagen vascular diseases (+) RA : 5, SjS : 3, MCTD : 1,PM : 1
Prednisolone (+) 55 (96.5)
Average in the starting dose 45.411.0 mg/day
mPSL pulse therapy (+) 27 (47.4)
Immunosuppressive agent (+) 2 (3.5)
Pleuritis (+) 22 (38.6)
Pericarditis (+) 11 (19.3)
Lupus nephritis(+) 21 (36.8)
Pulmonary involvements (+) 12 (21.1)
Neuropathy (+) 7 (12.3 )
Parentheses show perecentages, Values express as meanSD.
RA ; rheumatoid arthritis, SjS ; sjogren’s syndrome, MCTD ;
mixed connective tissue disease, PM ; polymyositis, mPSL ; meth-
ylprednisolone.
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Statistical analysis
All results are expressed as meanSD. Statisti-
cal analyses were performed using Statview soft-




Fifty five patients (96.5%) with SLE received the
therapy with corticosteroids using oral prednisolne
as the initial treatment (Table 1). Figure 2 shows
the starting dose of prednisolone : none (2 patients,
3.5%), 20 mg/day (none), 20-29 mg/day (3 pa-
tients, 5.3%), 30-39 mg/day (7 patients, 12.3%), 40-
49 mg/day (17 patients, 29.8%), 50-59 mg/day (17
patients, 29.8%), 60 mg/day (11 patients, 19.3%).
All of patients treated with corticosteroid received
over or equal to dose of 20 mg/day of prednisolone,
and the mean starting dose of prednisolone is 45.4
11.0 mg/day. The treatment with methylpredniso-
lone (mPSL) pulse therapy was carried out for 27
patients (47.4%) as the initial treatment (Table 1).
Immunosuppressive agent was carried out for 2
patients (3.5%) as the initial treatment. Cyclophos-
phamide was used in these two patients as the im-
munosuppressive agent.
Exacerbations
The exacerbation of SLE was found in 15 patients
(26.3%), 14 females and a male during the disease
course (Table 2 and Figure 3). The total number of
exacerbations observed in the 15 patients was 29
times. One exacerbation was observed in 9 patients,
2 exacerbations were in 3 patients, 3 exacerbations
in a patient, and 4 exacerbations in 3 patients. While
the mean disease duration of SLE patients with an
exacerbation was 12.34.8 years (3.8 - 17.5 years),
the time interval between the diagnosis of SLE and
the occurrence of the first exacerbation was 4.84.7
years on average (0.1 - 12.7 years) ; 1 year in 4 pa-
tients, 1 - 2.9 years in 4 patients, 3 - 4.9 years in a pa-
tient, 5 - 6.9 years in a patient, 7 - 8.9 years in 2 pa-
tients, and 11 - 12.9 years in 3 patients. The time in-
terval between the diagnosis of SLE and the occur-
rence of an exacerbation in all exacerbations was1
year in 4 patients, 1 - 2.9 years in 4 patients, 3 - 4.9
years in 5 patients, 5 - 6.9 years in 3 patients, 7 - 8.9
years in 7 patients, 9 - 10.9 years in a patient, and
11 - 12.9 years in 5 patients. The average dose of
prednisolone used to maintain before the first ex-
acerbation was 12.212.3 mg/day, and the dose
was increased in all patients to 45.814.7 mg/day
(Table 3). For the first exacerbation, 9 patients
Figure 2. The dose of prednisolone (mg/day) at the initial
therapy.









12 - 35 4 4
36 - 59 1 5
60 - 83 1 3
84 - 107 2 7
108 - 131 0 1
132 - 156 3 5
Total 15 29
Figure 3. Time course of exacerbations in 15 patients with
SLE who had at least one exacerbation.
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(60.0%) were treated with mPSL pulse therapy, and
one patient (0.7%) was with immunosuppressive
agent, mizoribin.
Comparison of clinical data between patients with
and without an exacerbation
Figure 4 shows the comparison of age at the
time of diagnosis of SLE between patients with and
without a subsequent exacerbation. The mean age
of patients with an exacerbation (33.110.2 y.o.)
was younger than those without it (42.718.5 y.o.)
though there was no significant difference. The per-
centage of patients with an exacerbation was 34.1%
of patients younger than 50 y.o., and 6.3% of pa-
tients over or equal to 50 y.o..
Contribution of the initial factors to an exacerba-
tion
Clinical findings at the time of diagnosis of SLE
were shown in Table 4 comparing between patients
with and without a subsequent exacerbation. The
percentage of patients who had lupus nephritis at
the time of the diagnosis was higher in patients with
an exacerbation (60.0%) than that in those without
it (19.0%). There was no difference in skin involve-
ments, arthritis, central nerve system (CNS) lupus,
pericarditis and pleuritis between patients with and
without a subsequent exacerbation. Table 5 shows
Table 3 The treatment for the first exacerbation
No. The dose of prednisolone used to maintainbefore the first exacerbation (mg/day)
Treatment
Prednisolone (mg/day) mPSL pulse therapy Immunosuppressive agent
1 12.5 40 + -
2 35 60 + -
3 10 50 + mizoribin
4 2.5 60 + -
5 7.5 50 + -
6 0 20 - -
7 5 40 - -
8 5 50 - -
9 17.5 45 - -
10 15 50 + -
11 0 60 + -
12 40 60 + -
13 22.5 60 + -
14 10 22.5 - -
15 0 20 - -
The average dose of prednisolone used to maintain before the first exacerbation was 12.212.3 mg/day. The dose of prednisolone
was increased to 45.814.7 mg/day for the treatment.
Figure 4. Age at the time of diagnosis of SLE. Open columns
show patients with a subsequent exacerbation, and closed col-
umns show those without a subsqeunt exacerbation.







Skin involvements 10 (66.7) 28 (66.7)
Arthritis 12 (80.0) 31 (73.8)
CNS lupus 0 (0.0) 3 ( 7.1)
Lupus nephritis 9 (60.0) 8 (19.0)
Pericarditis 4 (26.7) 6 (14.3)
Pleuritis 6 (40.0) 14 (33.3)
Parentheses show perecentages, CNS ; central nerve system
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the comparison of data in hematological and im-
munological tests at the time of the diagnosis be-
tween patients with and without a subsequent ex-
acerbation. The percentages of patients who had
decreased number of WBC and platelets, decreased
level of C3 and CH50, and the presence of anti-Sm
antibodies at the time of the diagnosis were higher
in patients with a subsequent exacerbation than in
those without it. Decreased level of C3 was found
more frequently in patients with positive anti-Sm
antibodies than in those with negative anti-Sm an-
tibodies (83.3% and 55.2%, respectively). The per-
centage of patients who had positive anti-dsDNA
antibody at the time of the diagnosis was not higher
in patients with a subsequent exacerbation than in
those without it.
The difference in treatment
The dose of prednisolone at the initial treatment
was compared between patients with and without
an exacerbation (Figure 5). All patients were treated
with more than or equal to 20 mg of prednisolone
except 2 cases treated without prednisolone. The
mean dose of prednisolone was not significantly dif-
ferent between patients with and without an exac-
erbation (46.311.1 mg/day and 43.311.0 mg/
day, respectively). There was no difference in per-
centages of patients with an exacerbation between
patients treated with and without mPSL pulse ther-
apy (22.2% and 30.0%, respectively) (Figure 6).
Table 5 Laboratory data at the time of diagnosis of SLE
Patients with exacerbation Patients without exacerbation
Leukopenia 6 / 6 (100) 20 / 40 (50.0)
Thrombocytopenia 3 / 5 (60.0) 8 / 39 (20.5)
Elevated ESR 4 / 4 (100) 28 / 34 (82.4)
Anti-dsDNA antibodies 6 / 11 (54.5) 30 / 39 (76.9)
Anti-Sm antibodies 3 / 4 (75.0) 4 / 35 (11.4)
Decreased C3 10 / 11 (90.9) 24 / 36 (66.7)
Decreased C4 7 / 11 (63.6) 23 / 36 (63.9)
Decreased CH50 11 / 11 (100) 27 / 37 (73.0)
Positive immune complexes 3 / 5 (60.0) 16 / 27 (59.3)
Positive anti-SS-A antibodies 1 / 4 (25.0) 14 / 32 (43.8)
Positive anti-SS-B antibodies 1 / 4 (25.0) 4 / 31 (12.9)
Parentheses show percentages, ESR ; erythrocyte sedimentation rates
Figure 5. The dose of prednisolone at the initial therapy. Open
columns show patients with a subsequent exacerbation, and
closed columns show those without a subsequent exacerbation.
Figure 6. The difference in occurrence of exacerbations be-
tween patients with and without the therapy with methylpred-
nisolone (mPSL) pulse at the time of diagnosis of SLE.
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Prognosis
Three patients died during the course. Their mean
age was 69.07.5 y.o.. Two patients died at 2 months
after the diagnosis during the initial treatment due
to disseminated intravascular coagulation and CNS
lupus. A patient died at 32 months after the diag-
nosis due to hepatic carcinoma.
DISCUSSION
The clinical course of SLE is characterized by
periods of exacerbations and remissions. In this
study, we examined how many times an exacerba-
tion took place in the course of SLE and determined
whether any factors distinguished those patients who
developed a subsequent exacerbation from those
who did not. Fifteen patients (26.3%) had exacer-
bations during the disease course. The total num-
ber of exacerbations in the 15 patients was 29 times.
While the mean disease duration of the follow up
is 12.34.8 years, the mean duration between the
diagnosis of SLE and the first exacerbation is 4.8
4.7 years. Swaak, et al. reported that exacerbations
were observed in 62 (56.4%) of 110 patients with
SLE (10). Bujan, et al. (11) demonstrated that, dur-
ing 9.5 years as the mean duration of the follow up,
SLE patients had a mean of 4.6 flares per patient,
18.9% had no flare, and major flares were 54.7%
among the total number of flares. The difference in
the percentage of exacerbations between our study
and the previous reports may be explained by that
in the severity of patients and the definition of an
exacerbation. For example, in the previous reports
an exacerbation was simply defined as any clinical
event attributable to the disease activity. On the
other hand, in our study, an exacerbation was de-
fined using 3 features of clinical and serological find-
ings, indicating that an exacerbation detected by
our definition was relatively severer than that in pre-
vious reports and needed any modifications of ther-
apy such as an increase of the dose of prednisolone.
The most commonly used corticosteroid in the
treatment of patients with SLE is oral prednisolone.
Prednisolone at doses up to 20 mg/day is used fre-
quently to treat symptoms of mild to moderate SLE,
and higher doses of 1 to 1.5 mg/kg body weight
prednisolone improves survival of patients with se-
vere SLE (12). In this study, oral prednisolone was
used in the initial therapy for 96.5% of patients with
SLE, and the starting dose of prednisolone was
more or equal to 20 mg/day in all patients. In the in-
itial therapy, the treatment with mPSL pulse ther-
apy was performed in 47.4% of patients with SLE
just before the treatment with oral prednisolone.
The therapy with mPSL pulse has commonly used
in the treatment of severe manifestations including
lupus nephritis (13, 14). Isenberg, et al. reported
that mPSL pulse therapy on patients with active SLE
was effective and safe (15). However, other studies
demonstrated that mPSL pulse therapy produces
greater immunosuppression and risk of osteoporotic
fractures than oral prednisolone (16 -18). On the
other hand, two patients received cyclophosphamide
as the initial therapy. Recent studies have shown
that both patients and renal survivals are signifi-
cantly better in patients receiving cyclophosphamide
in addition to oral prednisolone than those given
oral prednisolone alone (19-21). In this study, ad-
dition of immunosuppressive agent to prednisolone
was performed in 3.5% of SLE patients mainly for
the treatment of lupus nephritis.
This study showed that there was an indication
that mean age at the time of diagnosis of SLE was
younger in SLE patients with a subsequent exacer-
bation than in those without it. This is consistent
with data by Swaak, et al . (10) that younger patients
were more prone to develop an exacerbation. They
also showed that a relatively increased exacerbation
incidence was found in male patients compared with
female patients. However, our study could not show
the difference in the incidence of an exacerbation
between male and female because there were a few
numbers of male patients.
Patients who had lupus nephritis at the time of
the diagnosis showed a subsequent exacerbation
more frequently than those who did not. It has
been shown that at least 50% of patients with SLE
exhibit signs of nephritis during the disease course,
and nephritis with impaired renal function may be
a major cause of morbidity (22). Our data suggest
that the presence of lupus nephritis at the time of
the diagnosis may increase the risk of a subsequent
exacerbation. This study also showed that, in 13 pa-
tients with lupus nephritis who received mPSL pulse
therapy at the first treatment, a subsequent exac-
erbation was found in 5 patients but not in 8 pa-
tients. On the other hand, all patients (4 patients)
with lupus nephritis who did not receive mPSL pulse
therapy at the first treatment showed a subsequent
exacerbation. These data suggest that mPSL pulse
therapy at the first treatment is effective to decrease
the risk of a subsequent exacerbation in SLE pa-
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tients with lupus nephritis. In this study, there was
no difference in the presence of skin involvements,
arthritis, CNS lupus, pericarditis and pleuritis at the
time of the diagnosis between patients with and
without a subsequent exacerbation. In laboratory
tests, percentages of patients who had decreased
number of WBC and platelets, decreased levels of
C3 and CH50, and the presence of anti-Sm antibod-
ies at the time of the diagnosis were higher in pa-
tients with a subsequent exacerbation than in those
without it. Anti-Sm antibodies were prone to be posi-
tive in SLE patients with decreased level of com-
plements. A previous report has also shown that, at
the time of diagnosis, patients who developed a sub-
sequent exacerbation had the positive anti-Sm anti-
bodies more frequently than those who did not (10).
Anti-Sm antibodies have been identified in the sera
of about one-third of SLE patients (23), and have
been shown to have the ability to activate comple-
ments (24). Thus, anti-Sm antibodies may be a use-
ful marker in the activation of complements and a
subsequent exacerbation in SLE patients.
This study showed that there was no difference in
the initial dose of prednisolone between patients with
and without a subsequent exacerbation. The initial
dose of prednisolone was decided by the disease ac-
tivity of SLE at the time of the diagnosis. Similarly,
the treatment with mPSL pulse therapy was per-
formed to SLE patients with severe organ involve-
ments and high disease activity. Therefore, it may
be difficult to compare the clinical course between
patients who were treated with high dose of pred-
nisolone and mPSL pulse therapy and those who
were not because the disease activity at the time of
diagnosis was different between these two groups.
In summary, we have shown clinical series of SLE
patients with an exacerbation in our clinical depart-
ment. The data indicate that a relatively increased
exacerbation incidence was found in younger SLE
patients. Clinical and laboratory factors at onset to
influence a subsequent exacerbation are the pres-
ence of lupus nephritis, decreased number of WBC
and platelets, decreased level of complements and
the presence of anti-Sm antibodies. This study sug-
gests that SLE patients who are positive in these
parameters at onset require careful monitoring in
the disease course.
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